Anti-Human CD74 Reference Antibody (Milatuzumab, RUO)

Description: Milatuzumab (BS10159) is a research-grade recombinant antibody targeting CD74. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1.77mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: HLA-DRantigens-associatedinvariantchain,HLAclassIIhistocompatibilityantigengammachain,CD74,CLIP,Iaantigen-associatedinvariantchain,DHLAG,Ii
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: CD74-DOX(ADC),MEDI-115,hLL1,hLL1-DOX(ADC),CAS:899796-83-9
Background: HLA class II histocompatibility antigen gamma chain (CD74) is a ~33 kDa protein. Plays a critical role in MHC class II antigen processing by stabilizing peptide-free class II alpha/beta heterodimers in a complex soon after their synthesis and directing transport of the complex from the endoplasmic reticulum to the endosomal/lysosomal system where the antigen processing and binding of antigenic peptides to MHC class II takes place. Serves as cell surface receptor for the cytokine MIF.
Note: For research use only. Not suitable for clinical or therapeutic use.